Clinical Trials Logo

Stage II Breast Cancer clinical trials

View clinical trials related to Stage II Breast Cancer.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 3

NCT ID: NCT01372579 Active, not recruiting - Clinical trials for Stage IIIA Breast Cancer

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Start date: August 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well giving eribulin mesylate and carboplatin together before surgery works in treating patients with stage I-III triple-negative breast cancer. Drugs used in chemotherapy, such as eribulin mesylate and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

NCT ID: NCT01293032 Active, not recruiting - Clinical trials for Stage IIIA Breast Cancer

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

Start date: April 2011
Phase: N/A
Study type: Interventional

RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment and plan effective treatment. PURPOSE: This pilot study is studying how well hormone therapy or chemotherapy before surgery based on gene expression analysis works in treating patients with breast cancer. The purpose of this research study is threefold. First, it is to determine if this approach to treatment is acceptable to participants. Second, it is to determine whether it is feasible to use the genetic make-up of your breast cancer cells to predict whether your disease will best respond to chemotherapy or hormonal therapy when given prior to surgery. Third, which is optional, is to determine if the blood levels of Insulin-like growth factor binding protein-2 IGFBP-2 can be used to monitor the response of your breast cancer to the treatment that you receive.